三种乳腺癌化疗方案的药物经济学分析

Analysis of Pharmacoeconomic of Three Therapeutic Schemes for Mammary Cancer

关键词:  成本-效果  药物经济学  乳腺癌  敏感度分析

Key words:  cost-effectiveness analysis  pharmacoeconomics  mammary cancer  sensitivity analysis

摘要:

目的 从药物经济学角度评价乳腺癌术后3种化疗方案的经济学效果，为临床合理用药提供参考。方法 90例乳腺癌术后患者分为3组[TAC组（多西他赛+多柔比星+环磷酰胺）、PEC组（紫杉醇脂质体+表柔比星+环磷酰胺）、AC组（多柔比星+环磷酰胺）]，采用药物经济学的成本-效果分析法对3种化疗方案进行临床病例的回顾性分析比较。结果 3组化疗方案的总体有效率分别为71.87%，73.07%，65.62%；治疗成本分别为11 713.49元，18 197.79元和7 795.82元；成本-效果比分别为162.98，249.04，118.80。化疗不良反应方面，PEC组发生率高于TAC组及AC组。结论 TAC为乳腺癌术后化疗较佳的治疗方案，值得推广。

Abstract:

OBJECTIVE To evaluate the cost-effectiveness of three chemotherapy schemes in postoperative treatment of mammary cancer, providing a basis for the further drug administration. METHODS Ninety postoperative patients with mammary cancer were divided into three groups[TAC group (docetaxel + doxorubicin + cyclophosphamide), PEC group (paclitaxel + epirubicin + cyclophosphamide), and AC group (doxorubicin + cyclophosphamide)], the cost-effectiveness method in pharmacoeconomics was adopted to analyze retrospectively the three different regimens.RESULTS The overall response rate for TAC, PEC and AC were 71.87%, 73.07% and 65.62%, respectively; the costs were 11 713.49, 18 197.79 and 7 795.82 yuan, respectively, with corresponding cost-effectiveness ratios of 162.98, 249.04 and 118.80. For the chemotherapy toxicity, the PEC group was higher than those of the TAC group and AC group. CONCLUSION Scheme TAC is a better approach for postoperative treatment of soaked mammary cancer.